[A23-29] Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

Last updated 05.10.2023

Project no.:
A23-29

Commission:
Commission awarded on 03.04.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations; first-line treatment

Result of dossier assessment:
  • PD-L1 expression ≥ 50%: added benefit not proven
  • PD-L1 expression < 50%: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

05-10-2023 A G-BA decision was published.
G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form